Short answer
Arcutis Biotherapeutics, Inc. (ARQT) filed an 8-K current report with the SEC on June 9, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 8.01 (Other Events). Stockholders approved all three proposals at the June 5, 2026 annual meeting.
Arcutis Biotherapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders approved all three proposals at the June 5, 2026 annual meeting
- Three Class III directors elected through 2029; Watanabe and Krishnamohan received strongest support
- Ernst & Young LLP auditor ratification overwhelmingly approved, with 107,867,442 votes for
- Executive compensation received advisory approval, with 88,728,269 votes for versus 3,723,408 against
- 14,868,017 broker non-votes on director and compensation proposals limit interpretation of total shareholder sentiment
Item 8.01 · Other Events
- Revised non-employee director compensation program effective at the Annual Meeting
- Annual cash and equity compensation terms updated for eligible directors
- Changes aimed at director recruitment and retention, potentially increasing shareholder dilution or governance costs
- Full compensation terms available in Exhibit 10.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcutis Biotherapeutics, Inc. 8-K filings
Get the next ARQT 8-K as it lands
Follow ARQT for push alerts, or ask the research agent what this filing means.